Endurance Training in Patients With Post-TB Lung Disease

计划入组 36 人 · 首次发布于 2023 年 9 月 21 日

Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease

计划入组 760 人 · 首次发布于 2026 年 7 月 28 日

TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease

计划入组 23 人 · 首次发布于 2026 年 3 月 5 日

Lung Disease Therapy (Metis Pharmaceuticals)

lung inflammatory disease therapy (COPD)

TB-003B

Lung Therapeutics, Inc.

United States

Sec Lung, LLC

United States

THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC INCORPORATED IN THE STATE OF DELAWARE USA

South Africa

Experimental Cancer Drug Navitoclax Shows Promise in Enhancing Tuberculosis Treatment

Global TB Crisis Persists: CHEST 2024 Leaders Highlight Post-COVID Challenges and Rising Death Toll

bioAffinity Technologies Advances CyPath Lung into Post-Treatment Lung Cancer Surveillance